SML2956
Nalmefene Hydrochloride
≥98% (HPLC), μ-opioid receptor agonist, powder
别名:
(5a)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylene-morphinan-3,14-diol hydrochloride, NIH 1036, Nalmefene HCl
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H25NO3·HCl
化学文摘社编号:
分子量:
375.89
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
产品名称
Nalmefene Hydrochloride, ≥98% (HPLC)
InChI
1S/C21H25NO3.ClH/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13;/h4-5,13,16,19,23-24H,1-3,6-11H2;1H/t16-,19+,20+,21-;/m1./s1
SMILES string
C=C1CC[C@@]2(O)[C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]1OC5=C(C=C4)O.Cl
InChI key
GYWMRGWFQPSQLK-OPHZJPRHSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
naltrexone analogue; inverse agonist at the μ-opioid receptor (MOR) and as a weak partial agonist at the κ-opioid receptor
Nalmefene hydrochloride, a naltrexone analogue, is an inverse agonist at the μ-opioid receptor (MOR) and as a weak partial agonist at the κ-opioid receptor. Nalmefene hydrochloride is used as treatment for addiction.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Aquatic Chronic 1 - STOT SE 3
target_organs
Central nervous system
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Karl Mann et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 26(12), 1941-1949 (2016-11-16)
Nalmefene, a mu- and delta-opioid receptor (MOR, DOR) antagonist and a partial kappa-opioid receptor (KOR) agonist, is approved in the European Union and other countries for the reduction of alcohol consumption in alcohol dependent patients with a high drinking risk
Javier Calleja-Conde et al.
British journal of pharmacology, 173(16), 2490-2505 (2016-05-31)
The opioid antagonist nalmefene (selincro®) was approved for alcohol-related disorders by the European Medicines Agency in 2013. However, there have been no studies regarding the effectiveness of nalmefene when alcohol is used in combination with cocaine. Using operant alcohol self-administration
Bernadett I Gál et al.
Frontiers in pharmacology, 10, 1087-1087 (2019-10-16)
Nalmefene is approved for as-needed pharmacological treatment in alcohol use disorder (AUD) by the European Medicines Agency. While the cellular effects of nalmefene have been thoroughly investigated, data are very limited on how this agent influences neural signals associated with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持